HC Wainwright Expects Stronger Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Investment analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Pyxis Oncology in a report issued on Tuesday, March 24th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.35) per share for the quarter, up from their prior forecast of ($0.39). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.85) EPS, FY2028 earnings at ($0.34) EPS and FY2030 earnings at $0.83 EPS.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Royal Bank Of Canada decreased their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Wall Street Zen upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Stifel Nicolaus reduced their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Trading Down 5.8%

NASDAQ PYXS opened at $1.31 on Thursday. The firm’s 50 day simple moving average is $1.49 and its 200 day simple moving average is $2.49. The firm has a market capitalization of $82.31 million, a price-to-earnings ratio of -1.02 and a beta of 1.45. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The firm had revenue of $11.04 million during the quarter, compared to analyst estimates of $0.13 million.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of PYXS. Bank of America Corp DE lifted its stake in shares of Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after acquiring an additional 9,062 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Pyxis Oncology by 37.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock worth $58,000 after purchasing an additional 13,550 shares in the last quarter. Vanguard Group Inc. increased its holdings in Pyxis Oncology by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after purchasing an additional 14,566 shares in the last quarter. Velan Capital Investment Management LP raised its position in Pyxis Oncology by 37.5% in the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after purchasing an additional 15,000 shares during the last quarter. Finally, LPL Financial LLC raised its position in Pyxis Oncology by 150.7% in the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after purchasing an additional 21,100 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

Key Pyxis Oncology News

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and materially lifted multiple forward EPS forecasts (FY2026, FY2027, FY2028 and projected FY2030 profitability) and bumped several quarterly estimates — signaling improved multi‑year expectations and a $7 price target. These revisions are a bullish catalyst for upside longer term. HC Wainwright Lifts Earnings Estimates for Pyxis Oncology HC Wainwright Reaffirms Buy for Pyxis Oncology
• Neutral Sentiment: Market data shows an apparent zero reported short interest for March (likely a reporting artifact); this provides no reliable directional signal for near‑term price pressure.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed sales (most recently 13,896 shares at about $1.03). Insider exits can be viewed negatively by investors even if done for personal/liquidity reasons. Insider Selling Disclosure
• Negative Sentiment: Some sell‑side shops trimmed upside: Stifel lowered its price target (reducing implied upside), a sign that not all analysts are uniformly bullish. That can temper buying interest. Stifel Lowers Expectations for Pyxis Oncology
• Negative Sentiment: Within HC Wainwright’s note there was a downward revision to Q2‑2026 EPS (to -$0.36 from -$0.32), introducing mixed near‑term guidance despite the more positive multi‑year outlook — likely contributing to short‑term selling pressure.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.